Fig. 4.

Survival of vaccinated C57bl/6 mice after intraprostatic challenge. a C57bl/6 mice were subcutaneously vaccinated once a week for three consecutive weeks, followed by an intraprostatic RM-9 challenge in the fourth week and monitored for tumor development via transrectal ultrasonography (* P < 0.05 compared to the RM-9 vaccinated mice). b C57bl/6 mice were s.c. vaccinated with PBS or RM-9/mIL-7 once a week for three consecutive weeks, followed with an intraprostatic challenge with RM-9 or RM-9/mGM-CSF in the fourth week and was monitored for tumor development via transrectal ultrasonography and survival was determined (* P < 0.05 compared to RM-9/mIL-7 vaccinated mice challenged with an RM-9 challenge). c Immune histochemistry of endpoint tumors (tumor ≥ 1,000 mg) of mice challenged intraprostatically with either RM-9 or RM-9/mGM-CSF after vaccination with PBS or RM-9/mIL-7. Frozen sections were stained for HE or for CD4⁺, CD8⁺, CD11b⁺ or CD19⁺ cell markers and scored three times on three different days